Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 DevelopmentBusiness Wire • 05/11/26
Agenus (AGEN) Earnings Expected to Grow: What to Know Ahead of Q1 ReleaseZacks Investment Research • 05/04/26
Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026Business Wire • 04/21/26
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access ProgramsBusiness Wire • 04/21/26
Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal CancerBusiness Wire • 04/17/26
All You Need to Know About Agenus (AGEN) Rating Upgrade to Strong BuyZacks Investment Research • 04/03/26
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026Business Wire • 04/03/26
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal CancerBusiness Wire • 04/01/26
Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient AccessBusiness Wire • 03/26/26
Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal CancerBusiness Wire • 03/17/26
Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues RecognizedBusiness Wire • 03/16/26
Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing NeedsBusiness Wire • 03/10/26
Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate UpdateBusiness Wire • 03/04/26
Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BALBusiness Wire • 02/19/26
Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold TumorsBusiness Wire • 02/09/26